Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 5/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | F13A1 | P00488 | 1/20 | 0.36 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | TGM1 | P22735 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111903 | 0.89 | CHRNB2 (0.42) | THRBSIGMAR1MEN1KMT2AMAPT | |
| SCHEMBL14357354 | 0.88 | LTB4R (0.38) | LTB4RLTB4R2THRBSIGMAR1MEN1 | |
| SCHEMBL5115000 | 0.85 | BCHE (0.41) | THRBKMT2A | |
| SCHEMBL5119254 | 0.79 | PTGDR2 (0.38) | THRBSIGMAR1MEN1KMT2AKDM4E | |
| SCHEMBL13181407 | 0.79 | LTB4R (0.56) | LTB4RLTB4R2MAPTNPY5RALDH1A1 | |
| SCHEMBL5388723 | 0.79 | TAAR1 (0.39) | LTB4RLTB4R2SIGMAR1MEN1KMT2A | |
| SCHEMBL5393160 | 0.78 | CA1 (0.39) | THRBMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL12162029 | 0.78 | GPR119 (0.39) | THRBSIGMAR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23291183 | 0.77 | LTB4R (0.54) | LTB4RLTB4R2NPY5RKDM4EALDH1A1 | |
| SCHEMBL14357353 | 0.77 | NISCH (0.50) | LTB4RLTB4R2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7291642-B2 | Bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-06 | — | — | US | disclosed |
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100219-A1 | Novel bradykinin-B1 antagonists, process for their preparation and their use as medicaments | BDKRB1, BDKRB2, MRGPRX1 | LTB4R 17/4885LTB4R2 23/4885THRB 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.